34 results
PRER14A
SPRY
ARS Pharmaceuticals Inc
16 Sep 22
Preliminary revised proxy
4:56pm
stock) and (ii) $5.05, which is the average of high and low trading prices as reported on the Nasdaq Global Market within five business days prior to August 11, 2022.
Table 2: Fee Offset Claims and Sources
N/A
PREM14A
SPRY
ARS Pharmaceuticals Inc
11 Aug 22
Preliminary proxy related to merger
5:22pm
stock) and (ii) $5.05, which is the average of high and low trading prices as reported on the Nasdaq Global Market within five business days prior to August 11, 2022.
Table 2: Fee Offset Claims and Sources
N/A
DEFA14A
SPRY
ARS Pharmaceuticals Inc
22 Apr 21
Additional proxy soliciting materials
4:02pm
paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify
8-K
EX-99.1
rt1bgcpv n4u
29 Mar 21
Silverback Therapeutics Reports Fourth Quarter and Full Year 2020
4:11pm
8-K
EX-99.1
obwwk3neod6cbbu
9 May 24
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
4:08pm
8-K
EX-99.1
4qgtqcog0fng5putz3r
21 Mar 24
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:06pm
10-Q
g5b28dr 8aa9
13 May 21
Quarterly report
4:21pm
S-1
9vdthjns4n4dr2fn60u3
10 Nov 20
IPO registration
4:46pm
424B4
q5w61umptfzdx
4 Dec 20
Prospectus supplement with pricing info
4:04pm
S-1/A
p2yt qpt7gts0
30 Nov 20
IPO registration (amended)
6:06am
10-K
aus81ynpn
29 Mar 21
Annual report
4:13pm
DRS
v0ohbyng5f9
2 Oct 20
Draft registration statement
12:00am
S-1
EX-10.14
qu7x658
10 Nov 20
IPO registration
4:46pm